Crescent Biopharma, Inc.
CBIOHealthcare|Biotechnology|US
$13.54
+0.60 (+4.64%)
DCF Value
$20.78
Tangible Book / Share
$5.35
Cash / Share
$5.62
Ownership Breakdown
49.8%
Float
37.1M
Shares Outstanding
18.5M
Float Shares
Major Holders (40)
Combined: 313.5%
Holders of 5%+ from their latest Schedule 13D/13G filing in the last two years. Percentages are as of each filing date.
| Holder | Type | % of Class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Peter Evan Harwin | Individual | 18.53% | 5,643,482 | Dec 8, 2025 | 13D/G |
| Peter Harwin | Individual | 16.52% | 6,602,408 | Jul 20, 2026 | 13D/G |
| Fairmount Funds Management LLC | Investment adviser | 16.50% | 6,593,385 | Jul 20, 2026 | 13D/G |
| Tomas Kiselak | Individual | 16.50% | 6,593,385 | Jul 20, 2026 | 13D/G |
| Fairmount Healthcare Fund II L.P. | Partnership | 16.50% | 6,593,385 | Jul 20, 2026 | 13D/G |
| Abigail P. Johnson | Individual | 15.00% | 4,133,514 | Feb 5, 2026 | 13D/G |
| FMR LLC | Holding company | 15.00% | 4,133,514 | Feb 5, 2026 | 13D/G |
| Lampert Mark N | Individual | 9.99% | 1,387,863 | Aug 14, 2025 | 13D/G |
| BVF Inc/Il | Corporation | 9.99% | 1,387,863 | Aug 14, 2025 | 13D/G |
| BVF Partners L P/Il | IA, PN | 9.99% | 1,387,863 | Aug 14, 2025 | 13D/G |
| Bong Y. Koh | Individual | 9.50% | 2,666,064 | Feb 17, 2026 | 13D/G |
| Venrock Healthcare Capital Partners III, L.P. | Partnership | 9.50% | 2,666,064 | Feb 17, 2026 | 13D/G |
| VHCP Co-Investment Holdings III, LLC | Other | 9.50% | 2,666,064 | Feb 17, 2026 | 13D/G |
| Venrock Healthcare Capital Partners EG, L.P. | Partnership | 9.50% | 2,666,064 | Feb 17, 2026 | 13D/G |
| VHCP Management III, LLC | Other | 9.50% | 2,666,064 | Feb 17, 2026 | 13D/G |
| VHCP Management EG, LLC | Other | 9.50% | 2,666,064 | Feb 17, 2026 | 13D/G |
| Nimish Shah | Individual | 9.50% | 2,666,064 | Feb 17, 2026 | 13D/G |
| BVF GP Holdings LLC | Other | 9.40% | 1,300,856 | Aug 14, 2025 | 13D/G |
| Forbion Growth Opportunities Fund III Cooperatief U.A. | Other | 6.10% | 1,677,852 | Dec 11, 2025 | 13D/G |
| ForGrowth III PA B.V. | Other | 6.10% | 1,677,852 | Dec 11, 2025 | 13D/G |
| Forbion Growth III Management B.V. | Other | 6.10% | 1,677,852 | Dec 11, 2025 | 13D/G |
| BlackRock, Inc. | Holding company | 5.60% | 2,075,291 | Oct 27, 2026 | 13D/G |
| Vestal Point Capital, LP | IA, PN | 5.40% | 1,500,000 | Feb 17, 2026 | 13D/G |
| Ryan Wilder | HC, IN | 5.40% | 1,500,000 | Feb 17, 2026 | 13D/G |
| BVF I GP LLC | Other | 5.10% | 707,116 | Aug 14, 2025 | 13D/G |
| Biotechnology Value Fund L P | Partnership | 5.10% | 707,116 | Aug 14, 2025 | 13D/G |
| BVF II GP LLC | Other | 4.30% | 593,740 | Aug 14, 2025 | 13D/G |
| Biotechnology Value Fund II LP | Partnership | 4.30% | 593,740 | Aug 14, 2025 | 13D/G |
| Kevin Tang | Individual | 4.21% | 1,160,000 | May 15, 2026 | 13D/G |
| Tang Capital Management, LLC | Other | 4.21% | 1,160,000 | May 15, 2026 | 13D/G |
| Arsani William | HC, IN | 4.10% | 575,000 | Aug 14, 2025 | 13D/G |
| Logos Global Management GP LLC | HC, OO | 4.10% | 575,000 | Aug 14, 2025 | 13D/G |
| Logos Global Management LP | IA, PN | 4.10% | 575,000 | Aug 14, 2025 | 13D/G |
| Siren, L.L.C. | Other | 3.00% | 1,965,114 | Nov 12, 2024 | 13D/G |
| Raymond Debbane | Individual | 3.00% | 1,965,114 | Nov 12, 2024 | 13D/G |
| Invus Global Management, LLC | Other | 3.00% | 1,965,114 | Nov 12, 2024 | 13D/G |
| Invus Public Equities Advisors, LLC | Other | 3.00% | 1,965,114 | Nov 12, 2024 | 13D/G |
| Invus Public Equities, L.P. | Partnership | 3.00% | 1,965,114 | Nov 12, 2024 | 13D/G |
| Tang Capital Partners, LP | Partnership | 2.24% | 616,477 | May 15, 2026 | 13D/G |
| Tang Capital Partners International, LP | Partnership | 1.64% | 451,619 | May 15, 2026 | 13D/G |
Insider Trades (100)
Last 4 quarters: 4,400,329 acquired · 84,882 disposed
| Insider | Position | Date | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Lynch Ryan | See Remarks | Sep 16, 2026 | SELL | 240 | $17.90 | $4.3K | Form 4 |
| Pinkas Jan | Chief Scientific Officer | Sep 16, 2026 | SELL | 658 | $17.90 | $11.8K | Form 4 |
| Im Ellie Eunkyung | Chief Medical Officer | Sep 16, 2026 | SELL | 623 | $17.90 | $11.2K | Form 4 |
| Scalzo Richard William | Chief Financial Officer | Sep 16, 2026 | SELL | 568 | $17.90 | $10.2K | Form 4 |
| Bispham Barbara Harlin | See Remarks | Sep 16, 2026 | SELL | 620 | $17.90 | $11.1K | Form 4 |
| Brumm Joshua T | director, officer: Chief Executive Officer | Sep 16, 2026 | SELL | 1,610 | $17.90 | $28.8K | Form 4 |
| Brumm Joshua T | director, officer: Chief Executive Officer | Sep 18, 2026 | SELL | 7,837 | $16.71 | $131.0K | Form 4 |
| McNeill Jonathan | President and COO | Sep 16, 2026 | SELL | 731 | $17.90 | $13.1K | Form 4 |
| McNeill Jonathan | President and COO | Sep 18, 2026 | SELL | 3,839 | $16.71 | $64.1K | Form 4 |
| Fairmount Funds Management LLC | director, 10 percent owner: | Jul 16, 2026 | BUY | 853,450 | $14.50 | $12.4M | Form 4 |
| Fairmount Funds Management LLC | director, 10 percent owner: | Jul 16, 2026 | BUY | 525,897 | $0.00 | $525.90 | Form 4 |
| Lynch Ryan | See Remarks | Jun 22, 2026 | SELL | 465 | $17.99 | $8.4K | Form 4 |
| Pinkas Jan | Chief Scientific Officer | Jun 22, 2026 | SELL | 1,288 | $17.99 | $23.2K | Form 4 |
| Scalzo Richard William | Chief Financial Officer | Jun 22, 2026 | SELL | 1,112 | $17.99 | $20.0K | Form 4 |
| Bispham Barbara Harlin | See Remarks | Jun 22, 2026 | SELL | 1,218 | $17.99 | $21.9K | Form 4 |
| Im Ellie Eunkyung | Chief Medical Officer | Jun 22, 2026 | SELL | 1,219 | $17.99 | $21.9K | Form 4 |
| McNeill Jonathan | President and COO | Jun 22, 2026 | SELL | 20,549 | $17.99 | $369.7K | Form 4 |
| Brumm Joshua T | director, officer: Chief Executive Officer | Jun 22, 2026 | SELL | 42,305 | $17.99 | $761.1K | Form 4 |
| Violin Jonathan | director | Jun 2, 2026 | AWARD | 11,050 | $17.01 | $188.0K | Form 4 |
| Lubner David Charles | director | Jun 2, 2026 | AWARD | 11,050 | $17.01 | $188.0K | Form 4 |
| Balcom Alexandra | director | Jun 2, 2026 | AWARD | 11,050 | $17.01 | $188.0K | Form 4 |
| Moran Susan | director | Jun 2, 2026 | AWARD | 11,050 | $17.01 | $188.0K | Form 4 |
| Fairmount Funds Management LLC | director, 10 percent owner: | Jun 2, 2026 | AWARD | 11,050 | $17.01 | $188.0K | Form 4 |
| Pinkas Jan | Chief Scientific Officer | Dec 15, 2025 | AWARD | 70,025 | $13.21 | $925.0K | Form 4 |
| Pinkas Jan | Chief Scientific Officer | Dec 15, 2025 | AWARD | 5,000 | — | — | Form 4 |
| Pinkas Jan | Chief Scientific Officer | Dec 15, 2025 | AWARD | 17,507 | — | — | Form 4 |
| Doughty Christopher Grant | Chief Business Officer | Dec 15, 2025 | AWARD | 8,000 | — | — | Form 4 |
| Doughty Christopher Grant | Chief Business Officer | Dec 15, 2025 | AWARD | 58,855 | $13.21 | $777.5K | Form 4 |
| Doughty Christopher Grant | Chief Business Officer | Dec 15, 2025 | AWARD | 14,714 | — | — | Form 4 |
| Brumm Joshua T | director, officer: Chief Executive Officer | Dec 15, 2025 | AWARD | 10,000 | — | — | Form 4 |
| Brumm Joshua T | director, officer: Chief Executive Officer | Dec 15, 2025 | AWARD | 45,117 | — | — | Form 4 |
| Brumm Joshua T | director, officer: Chief Executive Officer | Dec 15, 2025 | AWARD | 180,467 | $13.21 | $2.4M | Form 4 |
| Scalzo Richard William | Chief Financial Officer | Dec 15, 2025 | AWARD | 57,688 | $13.21 | $762.1K | Form 4 |
| Scalzo Richard William | Chief Financial Officer | Dec 15, 2025 | AWARD | 5,000 | — | — | Form 4 |
| Scalzo Richard William | Chief Financial Officer | Dec 15, 2025 | AWARD | 14,422 | — | — | Form 4 |
| McNeill Jonathan | President and COO | Dec 15, 2025 | AWARD | 6,000 | — | — | Form 4 |
| McNeill Jonathan | President and COO | Dec 15, 2025 | AWARD | 19,507 | — | — | Form 4 |
| McNeill Jonathan | President and COO | Dec 15, 2025 | AWARD | 78,029 | $13.21 | $1.0M | Form 4 |
| Im Ellie Eunkyung | Chief Medical Officer | Dec 15, 2025 | AWARD | 65,190 | $13.21 | $861.2K | Form 4 |
| Im Ellie Eunkyung | Chief Medical Officer | Dec 15, 2025 | AWARD | 5,000 | — | — | Form 4 |
| Im Ellie Eunkyung | Chief Medical Officer | Dec 15, 2025 | AWARD | 16,298 | — | — | Form 4 |
| Lynch Ryan | See Remarks | Dec 15, 2025 | AWARD | 33,512 | $13.21 | $442.7K | Form 4 |
| Lynch Ryan | See Remarks | Dec 15, 2025 | AWARD | 4,000 | — | — | Form 4 |
| Lynch Ryan | See Remarks | Dec 15, 2025 | AWARD | 8,378 | — | — | Form 4 |
| Bispham Barbara Harlin | See Remarks | Dec 15, 2025 | AWARD | 72,185 | $13.21 | $953.6K | Form 4 |
| Bispham Barbara Harlin | See Remarks | Dec 15, 2025 | AWARD | 6,000 | — | — | Form 4 |
| Bispham Barbara Harlin | See Remarks | Dec 15, 2025 | AWARD | 12,422 | — | — | Form 4 |
| McNeill Jonathan | President and COO | Dec 8, 2025 | AWARD | 172,836 | $13.17 | $2.3M | Form 4 |
| Brumm Joshua T | director, officer: Chief Executive Officer | Dec 8, 2025 | AWARD | 345,672 | $13.17 | $4.6M | Form 4 |
| Fairmount Funds Management LLC | director, 10 percent owner: | Dec 4, 2025 | BUY | 1,360,000 | $13.41 | $18.2M | Form 4 |
| Fairmount Funds Management LLC | director, 10 percent owner: | Dec 4, 2025 | BUY | 131,434 | $0.00 | $131.43 | Form 4 |
| Pinkas Jan | Chief Scientific Officer | Jul 16, 2025 | AWARD | 142,474 | $13.14 | $1.9M | Form 4 |
| Pinkas Jan | officer | Jul 7, 2025 | OTHER | 0 | — | — | Form 4 |
| Im Ellie Eunkyung | Chief Medical Officer | Jun 13, 2025 | OTHER | 257,822 | $9.56 | $2.5M | Form 4 |
| Moran Susan | director | Jun 23, 2025 | AWARD | 9,023 | $15.30 | $138.1K | Form 4 |
| Fairmount Funds Management LLC | director, 10 percent owner: | Jun 23, 2025 | AWARD | 9,023 | $15.30 | $138.1K | Form 4 |
| Violin Jonathan | director | Jun 23, 2025 | AWARD | 9,023 | $15.30 | $138.1K | Form 4 |
| Balcom Alexandra | director | Jun 23, 2025 | AWARD | 9,023 | $15.30 | $138.1K | Form 4 |
| Lubner David Charles | director | Jun 23, 2025 | AWARD | 9,023 | $15.30 | $138.1K | Form 4 |
| Balcom Alexandra | director | Jun 13, 2025 | OTHER | 20,164 | $6.16 | $124.2K | Form 4 |
| Invus Public Equities, L.P. | 10 percent owner | Aug 7, 2024 | SELL | 61,488 | $0.18 | $11.2K | Form 4 |
| Invus Public Equities, L.P. | 10 percent owner | Aug 8, 2024 | SELL | 260,873 | $0.19 | $50.0K | Form 4 |
| Invus Public Equities, L.P. | 10 percent owner | Aug 5, 2024 | SELL | 164,523 | $0.19 | $31.0K | Form 4 |
| Invus Public Equities, L.P. | 10 percent owner | Aug 6, 2024 | SELL | 55,732 | $0.18 | $10.2K | Form 4 |
| Invus Public Equities, L.P. | 10 percent owner | Aug 1, 2024 | SELL | 63,564 | $0.22 | $13.7K | Form 4 |
| Invus Public Equities, L.P. | 10 percent owner | Aug 2, 2024 | SELL | 286,200 | $0.20 | $57.4K | Form 4 |
| Invus Public Equities, L.P. | 10 percent owner | Jul 26, 2024 | SELL | 258,335 | $0.24 | $62.4K | Form 4 |
| Invus Public Equities, L.P. | 10 percent owner | Jul 29, 2024 | SELL | 363,949 | $0.24 | $85.6K | Form 4 |
| Invus Public Equities, L.P. | 10 percent owner | Jul 30, 2024 | SELL | 756,835 | $0.22 | $167.2K | Form 4 |
| Siren, L.L.C. | 10 percent owner | Jul 25, 2024 | DISPOSED | 0 | — | — | Form 4 |
| Rock Edwin | Chief Medical Officer | Jun 21, 2024 | BUY | 115,000 | $0.27 | $30.7K | Form 4 |
| Rock Edwin | Chief Medical Officer | Jun 20, 2024 | BUY | 190,000 | $0.25 | $48.1K | Form 4 |
| Hahn Brian M. | SVP Finance, CFO | Jun 18, 2024 | BUY | 17,500 | $0.25 | $4.3K | Form 4 |
| Koenig Scott | director | May 1, 2024 | AWARD | 40,000 | $1.62 | $64.8K | Form 4 |
| Goldberg Mark Alan | director | May 1, 2024 | AWARD | 40,000 | $1.62 | $64.8K | Form 4 |
| PEARSON TIMOTHY R | director | May 1, 2024 | AWARD | 40,000 | $1.62 | $64.8K | Form 4 |
| King Rachel K. | director | May 1, 2024 | AWARD | 40,000 | $1.62 | $64.8K | Form 4 |
| Andrews Patricia S | director | May 1, 2024 | AWARD | 40,000 | $1.62 | $64.8K | Form 4 |
| Jackson Scott Thomas | director | May 1, 2024 | AWARD | 40,000 | $1.62 | $64.8K | Form 4 |
| JUNIUS DANIEL M | director | May 1, 2024 | AWARD | 40,000 | $1.62 | $64.8K | Form 4 |
| JUNIUS DANIEL M | director | Mar 29, 2024 | AWARD | 5,209 | $3.00 | $15.6K | Form 4 |
| King Rachel K. | director | Mar 29, 2024 | AWARD | 3,334 | $3.00 | $10.0K | Form 4 |
| Goldberg Mark Alan | director | Mar 29, 2024 | AWARD | 4,584 | $3.00 | $13.8K | Form 4 |
| Johnson Bruce S | SVP & Chief Commercial Officer | Jan 12, 2024 | AWARD | 250,000 | $3.11 | $777.5K | Form 4 |
| Semerjian Harout | director, officer: Chief Executive Officer | Jan 12, 2024 | AWARD | 695,000 | $3.11 | $2.2M | Form 4 |
| Rock Edwin | Chief Medical Officer | Jan 12, 2024 | AWARD | 250,000 | $3.11 | $777.5K | Form 4 |
| Rath Chinmaya | SVP and Chief Business Officer | Jan 12, 2024 | AWARD | 250,000 | $3.11 | $777.5K | Form 4 |
| Hahn Brian M. | SVP Finance, CFO | Jan 12, 2024 | AWARD | 250,000 | $3.11 | $777.5K | Form 4 |
| Andrews Patricia S | director | Dec 29, 2023 | AWARD | 5,191 | $2.36 | $12.3K | Form 4 |
| King Rachel K. | director | Dec 29, 2023 | AWARD | 4,238 | $2.36 | $10.0K | Form 4 |
| Goldberg Mark Alan | director | Dec 29, 2023 | AWARD | 5,827 | $2.36 | $13.8K | Form 4 |
| Goldberg Mark Alan | director | Sep 30, 2023 | AWARD | 9,167 | $1.50 | $13.8K | Form 4 |
| Andrews Patricia S | director | Sep 30, 2023 | AWARD | 8,167 | $1.50 | $12.3K | Form 4 |
| King Rachel K. | director | Sep 30, 2023 | AWARD | 6,667 | $1.50 | $10.0K | Form 4 |
| Rock Edwin | Chief Medical Officer | Sep 22, 2023 | BUY | 30,403 | $1.38 | $42.0K | Form 4 |
| Rock Edwin | Chief Medical Officer | Sep 21, 2023 | BUY | 35,000 | $1.38 | $48.3K | Form 4 |
| Koenig Scott | director | Jun 1, 2023 | OPTION EX. | 21,000 | $0.60 | $12.6K | Form 4 |
| Koenig Scott | director | Jun 1, 2023 | OPTION EX. | 21,000 | $0.60 | $12.6K | Form 4 |
| King Rachel K. | director | May 19, 2023 | AWARD | 35,000 | $1.98 | $69.3K | Form 4 |
| JUNIUS DANIEL M | director | May 19, 2023 | AWARD | 35,000 | $1.98 | $69.3K | Form 4 |